Advanced Drug Resistant Staphylococcus Detection Technology Exclusively Licensed to DxNA Receives First Patent Approval
St. George, Utah — July 7, 2016 — Antibiotic-resistant infections should be easier to detect, and hospitals could become safer, thanks to a technology developed by the Translational Genomics Research Institute (TGen) and Northern Arizona University (NAU), and protected under a patent issued by Australia.
Soon, similar patent approvals are expected by the U.S., Canada, European Union, Japan, Brazil and other nations for this “superbug” test developed by TGen and NAU, and exclusively licensed to DxNA LLC, a company based in St. George, Utah for implementation on the company’s proprietary sample to answer molecular diagnostic platform, The GeneSTAT System, which provides DNA based testing capabilities Anywhere, Anytime by Anybody.
“This rapid, 1-hour test will precisely identify a family of antibiotic-resistant Staph infections we broadly refer to as MRSA,” said Dr. Paul Keim, Director of TGen’s Pathogen Genomics Division, or TGen North, based in Flagstaff.
“We hope this technology will be adopted worldwide by hospitals and clinics, and will help identify and isolate these dangerous and difficult-to-eliminate infections that have come to plague our medical institutions,” said Dr. Keim, who also is the Cowden Endowed Chair of Microbiology at NAU, and Director of NAU’s Center for Microbial Genetics and Genomics (MGGen). “The result should be more rapid diagnosis, improved treatment of patients, and reduced medical costs.”
MRSA — Methicillin-resistant Staphylococcus aureus — is an antibiotic-resistant form of the Staph bacteria that annually kills more Americans than HIV.
While MRSA technically refers to one particular strain of Staph, the genomics-based test developed by TGen, NAU and DxNA can precisely detect multiple types of drug-resistant Staph bacterial infections, including drug resistant Coagulase Negative Staphylococcus, a much more common hospital acquired infection than MRSA.
Staph infections are the most common hospital-acquired or associated infections. While most of the focus over the past few years has been on MRSA, in terms of incidence and total cost, drug resistant strains of Staph other than MRSA are a much more common problem.
Due to the increasing use of implantable biomaterials and medical devices, infections are increasingly caused by Coagulase Negative Staphylococcus (CNS). This is a type of Staph that is often resistant to multiple antibiotics and has a particular affinity for these devices.
“Rapid identification and differentiation of these resistant bacteria is key to optimizing treatment decisions that significantly impact patient outcomes and cost of care,” said David Taus, CEO of DxNA LLC. “Given that resistant CNS is a frequent pathogen in surgical site infections, orthopedic and cardiac device infections, and blood stream infections — among others — it is critical that we be able to rapidly identify and determine antibiotic resistance to provide for appropriate pre-surgical antibiotic prophylaxis to prevent infections and early and effective treatment when these infections do occur.”
Current molecular tests for MRSA all ignore CNS, rendering their results significantly less useful in treating patients given that drug resistant CNS infections are many times more common than MRSA.
DxNA’s Staphylococcus Test identifies and differentiates resistant and non-resistant strains of Staph and CNS. The test uses three separate proprietary biomarker targets and a proprietary methodology to determine which types of Staph are present, and which carry the gene that causes antibiotic-resistance in these bacteria.
“The test also is effective in identifying infected specimens where there are multiple types of Staph. The test will rapidly provide broader clinically-actionable results, improving antibiotic prophylaxis, early targeted intervention resulting in more effective treatment at lower costs,” Taus said.
About DxNA LLC
DxNA is a privately held company located in St. George Utah. It is a molecular diagnostics company that develops and distributes portable, fully-integrated systems and tests for infectious disease in the medical, agricultural, food safety, and biosecurity markets. The Company's systems and technologies enable rapid and precise molecular testing to take place on-site by allowing for otherwise complex laboratory procedures to be performed almost anywhere. DxNA's patented GeneSTAT® portable Real Time PCR molecular diagnostic testing system will allow individuals with minimal training to conduct accurate real-time diagnostic testing in virtually any location including laboratories, clinics, physician offices, emergency rooms or field settings. Designed with economy in mind, GeneSTAT is inherently less costly than the real time PCR systems typical of clinical laboratories. For more information visit: www.DxNA.com
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with neurological disorders, cancer, and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen.
About Northern Arizona University
Northern Arizona University is a high-research university with a statewide enrollment of 28,000 students. More than 20,000 students attend the Flagstaff campus, with 8,000 students enrolled online and at Extended Campus sites statewide. Research in genetics, forestry and ecology has drawn international recognition to the university, which also is highly regarded for its education, business and engineering programs. NAU launched competency-based Personalized Learning in 2013, the first self-paced, online education program that cuts the cost and time to an undergraduate degree.